Catalyst Watch: FOMC, FedEx Earnings, Electronic Arts Event, and Triple Witching Day
William Blair Initiates Zevra Therapeutics(ZVRA.US) With Buy Rating
William Blair analyst Sami Corwin initiates coverage on $Zevra Therapeutics(ZVRA.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 36.4% and a total average return
William Blair Keeps Their Buy Rating on Zevra Therapeutics (ZVRA)
Zevra Therapeutics Presents Five Posters At SSIEM 2024 Symposium Highlighting Arimoclomol's Efficacy In Treating Niemann-Pick Disease Type C And Data On OLPRUVA For Urea Cycle Disorders
Zevra Therapeutics to Participate at Upcoming Investor Conferences
Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session